InflaRx N.V. Common Stock (IFRX)

FairStock Score: 27/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable economics, honest earnings, and a margin of safety. InflaRx is a 65-employee clinical-stage biotech developing vilobelimab, a first-in-class anti-human C5a antibody in Phase 3 for early septic organ dysfunction. A successful drug could matter, but today there is no commercial product, no proven pricing power, and no durable moat. The latest reported quarter, the quarter labeled fiscal Q4 2025, showed revenue of -$33,931 and net income of -$10.6M. Trailing free cash flow is -$23.8M, a -21.2% FCF yield against a $112.4M market cap—all FairStock calculations. At the $1.55 close on 2026-10-13, FairStock calculations show P/B of 1.35 and P/E of -2.72. Debt is tiny with D/E 0.01, but FairStock calculations put ROE at -38.52% and ROCE at -18.54%. FairStock calculations also show an Altman Z-score of 0.74 and a Piotroski F-Score of 5/9. The FairStock Score is 27/100. The 52-week range of $0.80-$2.95 and beta of 2.54 show extreme volatility. The Lynch category is none because there are only 0 years of filed results, while 3 are needed. Growth depends almost entirely on clinical trial outcomes and financing. At the current price, book value does not substitute for earning power, and I see no Graham-style margin of safety. This is a pipeline option, not a compounding business.

In plain English: InflaRx is a small biotech developing a drug to calm harmful inflammation, mainly for serious conditions like septic organ dysfunction. It has no steady product sales and is losing money, so the business looks weak and unproven. The stock trades at $1.55, but because profits are negative and cash is burning, it is hard to call it cheap based on ordinary business numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer